Salute e Benessere

NOTICE OF EXTRAORDINARY GENERAL MEETING IN MENDUS AB (PUBL)

Press Release Stockholm, Sweden, November 13, 2023 The shareholders of Mendus AB (publ) (the “ Company ”), reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting (“ EGM ”) on Wednesday, 13 December 2023, at 16:00, at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm. Registration for the meeting will commence at 15:30.NOTIFICATIONShareholders who wish to attend the meeting must: (i) both be recorded in the share register maintained by...
Nasdaq GlobeNewswire
13/11/2023

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum…

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Amplyx Pharmaceuticals, Inc., an affiliate of Pfizer Inc., to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate...
Nasdaq GlobeNewswire
13/11/2023

Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for…

Saint-Herblain (France), November 13, 2023–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive pivotal Phase 3 immunogenicity data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553. These results complement the initial Phase 3 safety data the Company reported for the trial in August 2023 1.Funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union's...
Nasdaq GlobeNewswire
13/11/2023

Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces…

PRESS RELEASE - 13 November 2023, 07:00 CET Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual MeetingMechelen, Belgium and Itasca (IL), United States, 13 November 2023– Biocartis, an innovative molecular diagnostics company, announces today that it will host a free corporate workshop at the Annual Meeting of the 'Association for Molecular Pathology' (AMP), a leading molecular diagnostics conference, taking place between 14-18...
Nasdaq GlobeNewswire
13/11/2023

Guardant Health launches Shield blood-based screening test for colorectal cancer…

Early detection is essential to reduce colorectal cancer mortality. Colonoscopy and faecal tests are generally used for early detection, however, compliance rates for these screening tests are low and have remained stagnant since 2014.4 The primary reasons for lack of compliance with CRC screening recommendations include not having any symptoms of CRC, lack of time for a colonoscopy procedure, which requires a few days of preparation, and fear of an invasive colonoscopy procedure.4 Since the…
PR Newswire
13/11/2023

First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based…

To date, 242 patients have been treated across eight Phase I and II studies of TLX591, including Telix's ProstACT SELECT study (ClinicalTrials.gov ID: NCT04786847), which confirmed the clinical validity of Telix's optimal fractionated dosing and product safety profile. Prior published Phase II (single-arm) study data reported a 42.3 month overall survival (OS) and an acceptable safety profile when delivered under a fractionated dosing regimen administered concurrently with docetaxel…
PR Newswire
13/11/2023

FibroScan® by Echosens Recognized in AASLD Practice Guidance on Managing Portal…

The guidance, titled "AASLD Practice Guidance on Risk Stratification and Management of Portal Hypertension and Varices in Cirrhosis," provides a detailed outline for using liver stiffness measurement (LSM) by transient elastography (TE) to stage advanced chronic liver disease (ACLD), identify clinically significant portal hypertension (CSPH), and to determine the stage-specific role of upper endoscopy to identify varices needing treatment (VNT). The guidance, titled " AASLD…
PR Newswire
11/11/2023

Sequana Medical announces results of Extraordinary General Meeting of…

PRESS RELEASE REGULATED INFORMATION10 November 2023, 06:00 pm CETIds van der Weij appointed as non-executive directorGhent, Belgium – 10 November 2023– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Extraordinary General Meeting of Shareholders were approved at the...
Nasdaq GlobeNewswire
10/11/2023

Radiotherapy Market Worth $8.8 Billion | MarketsandMarkets

Browse in-depth TOC on "Radiotherapy Market" Browse in-depth TOC on "Radiotherapy Market" 54 - Tables 35 - Figures 300 - Pages Radiotherapy Market Scope: The external beam radiotherapy segment, by procedure, is expected to register the largest market share of the global radiotherapy systems market in 2023. Based on procedure, the radiotherapy market is segmented into external beam radiotherapy, internal beam radiotherapy/brachytherapy, and systemic...
PR Newswire
10/11/2023

Power Tools Market size worth $ 52.42 Billion, Globally, by 2030 at 5% CAGR…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=6479 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=6479 Browse in-depth TOCon" Power Tools Market " 202 - Pages 126 – Tables 37 – Figures Groundbreaking Insights Unveiled in the Global Power Tools Market Unveiling Insights into the Thriving Power Tools Market: A Resilient Landscape Amidst Challenges In the dynamic realm of industrial tools,...
PR Newswire
10/11/2023

Gastric Cancer Diagnostic Market to Reach $3.8 Billion, Globally, by 2032 at…

Request Sample of the Report on Gastric Cancer Diagnostic Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/210860 Prime determinants of growth Increase in incidence of gastric cancer, advancements in diagnostic technologies, growing awareness about gastric cancer drive the growth of the global gastric cancer diagnostic market. However, the high diagnostic cost for restricts market growth. Moreover, the significant unmet need in cancer diagnosis...
PR Newswire
10/11/2023

Surgical Gloves Market to Reach $1.8 Billion, Globally, by 2032 at 4.5% CAGR…

Request Sample of the Report on Surgical Gloves Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/66073 Request Sample of the Report on Surgical Gloves Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/66073 Prime determinants of growth Growth in R&D activities, rise in the prevalence of chronic conditions that require surgical interventions and growth in awareness regarding the use of surgical gloves to minimize contamination...
PR Newswire
10/11/2023

TAVR Embolic Protection Market to Reach $405.4 Million, Globally, by 2032 at 14%…

Request Sample of the Report on TAVR Embolic Protection Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/74889 Request Sample of the Report on TAVR Embolic Protection Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/74889 Prime determinants of growth Growth in R&D activities; rise in prevalence of cardiovascular diseases, including aortic stenosis; and rise in awareness regarding use of TAVR embolic protection devices to...
PR Newswire
10/11/2023

Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market…

The emergence of biosimilars has ushered in a transformative era within the realm of oncology treatments. These biosimilars, which offer more cost-effective alternatives to biologic cancer medications, have had a profound impact on patient access and market dynamics. The emergence of biosimilars has ushered in a transformative era within the realm of oncology treatments. These biosimilars, which offer more cost-effective alternatives to biologic cancer medications, have had a profound impact…
PR Newswire
10/11/2023

Hearing Implants Market to Reach $3.8 Billion, Globally, by 2032 at 8.2% CAGR…

Request Sample of the Report on Hearing Implants Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/2019 Request Sample of the Report on Hearing Implants Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/2019 Prime determinants of growth Growth in R&D activities, rise in prevalence of hearing disorders and growth in awareness regarding the use of hearing implants to minimize contamination risk are the factors that drive the...
PR Newswire
10/11/2023

STADA and Alvotech receive positive CHMP opinion for Europe's first ustekinumab…

CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity data, including AVT04-GL-301 study for pharmacokinetic similarity in healthy subjects and confirmatory comparative efficacy and safety clinical trial in patients with moderate to severe chronic...
Nasdaq GlobeNewswire
10/11/2023

Pharming Group provides updates on EMA regulatory review of leniolisib MAA and…

Leiden, The Netherlands, November 10, 2023:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has received a Day 180 Second List of Outstanding Issues (LoOI) from the European Medicines Agency's (EMA) Committee for Human Medicinal Products (CHMP) regarding its Marketing Authorisation Application (MAA) for leniolisib for adult and pediatric patients 12 years of age and older with APDS, a rare primary immunodeficiency. Based on the...
Nasdaq GlobeNewswire
10/11/2023

RZNOMICS Inc. Announces Clinical Trial Collaboration and Supply Agreement to…

RZ-001 has demonstrated therapeutic activity in preclinical studies and significant improvement in anti-cancer efficacy in a dose dependent manner in combination with atezolizumab. The clinical study will evaluate the safety and efficacy in liver cancer patients and it is anticipated that the combination of RZ-001 with atezolizumab may enhance response rate and anti-cancer efficacy that could benefit patients with HCC. RZ-001 has demonstrated therapeutic activity in preclinical studies and...
PR Newswire
10/11/2023

Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar…

Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicinesNew penicillin production process will significantly improve ecological footprint and help secure European-based supplyCutting-edge development hub will play key role in supporting long-term growth of leading biosimilar businessBasel, November 10, 2023– Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing...
Nasdaq GlobeNewswire
10/11/2023

Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001

GBM is known as the most malignant tumor in Central Nervous system with high mortality rate but lacks effective therapies. RZ-001, the RNA replacement enzyme-based cancer gene therapy for the treatment of GBM, targets and cleaves hTERT mRNA and replaces the mRNA with the therapeutic gene RNA. This induces anti-cancer activity and cytotoxic effect by trans-ligating an HSVtk-encoding sequence into the reprogrammed hTERT mRNA. RZ-001 has demonstrated very promising responses in preclinical studies…
PR Newswire
10/11/2023

Seegene Earns Improved ESG Rating from the Korea Institute of Corporate…

KCGS, one of the major ESG evaluation agencies in South Korea, annually rates the level of sustainable management, in the categories of environmental, social and governance, of domestically listed companies. The agency rates companies based on the following scale – S, A+, A, B+, B, C and D. KCGS, one of the major ESG evaluation agencies inSouth Korea, annually rates the level of sustainable management, in the categories of environmental, social and governance, of domestically listed…
PR Newswire
10/11/2023

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 10 November 2023— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and...
Nasdaq GlobeNewswire
10/11/2023

Shaping Global Policy: IFPA's Psoriatic Disease Response Index in the Western…

Psoriatic disease is not only complex but also burdensome, making access to treatment and care crucial indicators of overall healthcare system performance. Individuals living with chronic conditions like psoriatic disease often face challenging environments. The Psoriatic Disease Response Index serves as a catalyst for change, shedding light on the barriers to and enablers of healthcare system responsiveness. Psoriatic disease is not only complex but also burdensome, making access to…
PR Newswire
10/11/2023

Aino Health AB (publ): Interim report january-september 2023

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. 100,000 implemented licenses. Improved net sales, profitability and cashflow January – September 2023 Net sales were KSEK 17,605 (15,248)Profit/loss after financial items was KSEK -6,812 (-10,522) Earnings per share were SEK -0.2 (-0.3)July – September 2023Net sales were KSEK 5,633 (4,839) Profit/loss after financial items was...
Nasdaq GlobeNewswire
10/11/2023
Altri  Comunicati